NGS-based RNA-sequencing Market is predicted to reach USD 12.4 billion at a CAGR of 21.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global NGS-based RNA-sequencing Market”.

The NGS-based RNA-sequencing Market is estimated to register a CAGR of 21.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global NGS-based RNA-sequencing Market— Illumina (the U.S.), Thermo Fischer Scientific (the U.S.), Oxford Nanopore Agilent Technologies, Inc. (the U.S.) 149, BGI (China), PerkinElmer Inc. (the U.S.), QIAGEN (Germany), Eurofins Scientific (Luxembourg), Hoffmann-La Roche Ltd (Switzerland), Takara Bio Inc. (Japan), Tecan Genomics, Inc. (Switzerland).

NGS-based RNA-sequencing Market Highlights

The global NGS-based RNA-sequencing Market is accounted to register a CAGR of 21.00% during the forecast period and is estimated to reach USD 12.4 billion by 2032.

The continuous advancement of Next-Generation Sequencing (NGS) technologies has significantly reduced costs while boosting the speed and accuracy of RNA sequencing. This makes NGS-based RNA-sequencing more accessible and attractive for research and clinical diagnostics, driving market expansion. Furthermore, even as the cost of NGS technology has decreased, the initial cost of NGS equipment and ongoing fees for reagents, maintenance, and data processing remain costly for some organizations. NGS-based RNA-sequencing is increasingly being used in clinical diagnostics to identify and understand genetic diseases. This includes applications in cancer diagnosis, infectious diseases, and genetic anomalies, paving the way for more personalized and effective treatments. Additionally, sample preparation for NGS-based RNA-sequencing is difficult and error-prone, reducing the precision of the data. This intricacy necessitates skilled personnel and increases the time and cost associated with RNA sequencing initiatives, lowering market demand.

Segmental Analysis

The global NGS-based RNA-sequencing Market has been segmented based on Product and Service, Technology, Application, and End-use.

Product and Service segment the market into Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services and Data Analysis, Storage and Management. The sequencing platforms and consumables sector is predicted to dominate the NGS-based RNA-sequencing Market due to their critical role in the sequencing process. Sequencing platforms and consumables are crucial components of RNA sequencing because they directly impact the efficiency, accuracy, and throughput of the sequencing processes.

Technology segmented the market into Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing (SMRT), and Nanopore Sequencing. The Sequencing by Synthesis (SBS) category is expected to have the largest revenue share throughout the projection period, owing to its widespread use in academic research and clinical diagnostics due to its high throughput, precision, and cost-effectiveness in comparison to other sequencing methods.

Application has divided the worldwide NGS-based RNA-sequencing Market into Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling and Transcriptome Epigenetics. The expression profiling analysis sector is expected to expand the most in the market throughout the projected period, owing to its importance in understanding gene function, regulation, and the genetic basis of disease.

The global NGS-based RNA-sequencing Market is divided into three segments based on End-use: Research and Academia, Hospitals and Clinics, and Pharmaceutical and Biotechnology Companies. The Research and Academia category will hold a large market share during the forecast period. Academic and research institutions are the key income sources for the global NGS-based RNA-sequencing market. The cluster includes laboratories from research institutes, universities, government entities, biotechnology organizations, and pharmaceutical firms.

Regional Analysis

The global NGS-based RNA-sequencing Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe NGS-based RNA-sequencing Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The NGS-based RNA-sequencing Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World NGS-based RNA-sequencing Market comprises the Middle East, Africa, and Latin America.

North America is expected to dominate the NGS-based RNA-sequencing market throughout the forecast period. North America, particularly the United States, has a robust research infrastructure, with numerous top universities, research organizations, and biotech firms. This climate fosters innovation and rapid adoption of NGS-based RNA-sequencing technologies, enabling the area to dominate the market. Significant public and private investment in North America's healthcare and biotechnology industries allows for advanced study, development, and use of NGS-based RNA-sequencing. This financial support accelerates technological innovations and their deployment in healthcare settings.

Moreover, the European market is predicted to have rapid revenue growth throughout the forecast period. The sector is driven by factors such as the proliferation of academic and research institutes, as well as an increase in demand for personalized therapy. Furthermore, the region has a robust legislative framework in place to support genomics research, which is projected to fuel market revenue growth.

Additionally, Asia Pacific is expected to expand at the fastest CAGR in the NGS-based RNA-sequencing Market over the forecast period. The region's healthcare sector is quickly developing, aided by rising investment and government initiatives to improve infrastructure. This expansion promotes the use of cutting-edge technologies like NGS-based RNA-sequencing in diagnosis and research. Precision medicine is becoming increasingly relevant in Asia Pacific countries, with the goal of providing patient-specific treatments based on genetic information. Because of its usefulness in investigating genetic variations, NGS-based RNA-sequencing is gaining popularity.

The remaining NGS-based RNA-sequencing Market is segmented into three regions: the Middle East, Africa, and Latin America. These region's prevalence of genetic defects and cancer is rising, necessitating the employment of cutting-edge diagnostic tools. NGS-based RNA-sequencing provides detailed insights into genetic information, enabling early identification and personalized treatment regimens.

Key Findings of the Study

• The global NGS-based RNA-sequencing Market is expected to reach USD 12.4 billion by 2032, at a CAGR of 21.00% during the forecast period.


• Asia Pacific is expected to expand at the fastest CAGR in the NGS-based RNA-sequencing Market over the forecast period, which will be aided by rising investment and government initiatives to improve infrastructure.


• Based on End-user, the Research and Academia category will hold a large market share during the forecast period.


• Illumina (the U.S.), Thermo Fischer Scientific (the U.S.), Oxford Nanopore Agilent Technologies, Inc. (the U.S.) 149, BGI (China), PerkinElmer Inc. (the U.S.), QIAGEN (Germany), Eurofins Scientific (Luxembourg), Hoffmann-La Roche Ltd (Switzerland), Takara Bio Inc. (Japan), and Tecan Genomics, Inc. (Switzerland) are the key market players.